A Phase 1 interventional study of Lactose (inactive placebo) and midomafetamine HCl in Psychological Effects of Study Drug, sponsored by Lykos Therapeutics. Completed at 3 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to study MDMA-assisted therapy in healthy volunteers. The main question it aims to answer is:
Do two sessions of MDMA-assisted therapy result in changes in mood, emotional closeness to self and others, and other psychological symptoms?
Researchers will compare MDMA-assisted therapy to placebo with therapy.
Participants will have a non-drug preparatory session prior to each experimental session and an integrative session after each experimental session. Participants who received MDMA will crossover to receive placebo and placebo participants will crossover to receive MDMA.
This study is a Phase 1 study for up to a hundred people, The information gathered during this study may help us better understand the psychological effects produced by MDMA and how those effects can more effectively be used within a therapeutic context, as with people with PTSD. Participants will be healthy volunteers who have completed a program training them in conducting MDMA-assisted psychotherapy. In this randomized, double blind study, subjects will receive placebo and MDMA during two sessions scheduled at least two days apart in a psychotherapy setting. Mood, self-reported interpersonal closeness, psychological symptoms, blood pressure, heart rate and body temperature will be measured, and personality will be measured prior to the first therapy-like session and two months after the second session.
The study will follow a cross-over design, meaning that all participants will receive both MDMA and placebo, with order of session randomly assigned. Study participants will have a preparatory session prior to each experimental session and an integrative session after each session. The researchers will contact them via telephone one and two months after the second experimental session. By comparing changes in mood, feelings of emotional closeness to the self and others and psychological symptoms after placebo and after MDMA, the investigators hope to learn something about the effects of MDMA on mood, subjective experience and the way we think and feel about others.
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant receives inactive placebo during day-long experimental session.
Drug: Lactose (inactive placebo)
Participant receives 120 mg midomafetamine HCl possibly followed by 40 mg midomafetamine HCl during a day-long experimental session.
Drug: midomafetamine HCl
Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
Also known as: placebo
120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
Also known as: midomafetamine, MDMA, 3,4-methylenedioxymethamphetamine, MDMA HCl
Profile of Mood States (POMS)
Assesses current mood state
Time frame: Experimental session approximately six hours after drug administration
Profile of Mood States (POMS)
Assesses current mood state
Time frame: Day prior to each experimental session
Profile of Mood States (POMS)
Assesses current mood state
Time frame: Day after each experimental session
Interpersonal closeness measure
Visual analog scale assessing emotional closeness to self and four other targets
Time frame: Day prior to experimental session
Interpersonal closeness measure
Visual analog scale assessing emotional closeness to self and four other targets
Time frame: Day of experimental session approximately six hours post-drug administration
Interpersonal closeness measure
Visual analog scale assessing emotional closeness to self and four other targets
Time frame: Day after each experimental session
Brief Symptom Inventory (BSI)
Self-report measure assessing psychiatric symptoms
Time frame: Day prior to each experimental session
Brief Symptom Inventory (BSI)
Self-report measure assessing psychiatric symptoms
Time frame: Day of experimental session prior to drug administration
Brief Symptom Inventory (BSI)
Self-report measure assessing psychiatric symptoms
Time frame: Day of experimental session approximately five to six hours after drug administration
Brief Symptom Inventory (BSI)
Self-report measure assessing psychiatric symptoms
Time frame: Day after each experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Day prior to each experimental session
Neuroticism Extroversion Openness Personality Inventory
Self-report measure of five personality factors; Neuroticism, extroversion, openness to experience, conscientiousness and agreeableness
Time frame: At baseline
Neuroticism Extroversion Openness Personality Inventory
Self-report measure of five personality factors; Neuroticism, extroversion, openness to experience, conscientiousness and agreeableness
Time frame: Two months after the second experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Day after each experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: One month after the second experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Two months after the second experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Day six and 12 of telephone contact after second experimental session
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Day of each experimental session prior to drug administration
Columbia Suicide Severity Rating Scale (adapted C-SSRS)
Clinician-administered measure of suicide risk
Time frame: Day of each experimental session approximately five to six hours after drug administration
Blood pressure (SBP/DBP)
Periodic assessment of participant blood pressure during both experimental sessions.
Time frame: Throughout each experimental session, every 15 minutes for 6 hours, then every 30 minutes for 2 hours
Heart rate (pulse)
Periodic assessment of participant pulse during both experimental sessions.
Time frame: Throughout each experimental session, every 15 minutes for 6 hours, then every 30 minutes for 2 hours
Body temperature
Periodic assessment of participant body temperature during both experimental sessions.
Time frame: Approximately every 60 minutes for each experimental session
Ran from Apr 2011 to primary completion in Aug 2022, 135 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine